Literature DB >> 30771687

Unfractionated Heparin Alleviates Sepsis-Induced Acute Lung Injury by Protecting Tight Junctions.

Yina Liu1, Shengtian Mu2, Xu Li1, Yingjian Liang1, Liang Wang1, Xiaochun Ma3.   

Abstract

BACKGROUND: Unfractionated heparin (UFH) has been shown to ameliorate lung edema and lung vascular leakage in lipopolysaccharide-induced lung injury. Impaired tight junction (TJ) function is a sign of sepsis-induced acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), which is closely related to the downregulated expression of TJ-specific proteins or the upregulated expression of inflammatory cytokines. Because UFH has been intensively studied in modulating inflammation, we hypothesize that UFH may play a positive role in treating sepsis-induced ARDS/ALI by protecting TJs.
MATERIAL AND METHODS: Rat sepsis-induced lung injury was induced by cecal ligation and puncture and treated with UFH. Hematoxylin and eosin staining, lung wet/dry weight (W/D) ratio, and pulmonary microvascular leakage were evaluated to assess lung injury. Cytokines in bronchoalveolar lavage fluid were detected to determine lung inflammation. A transendothelial electrical resistance assay, a Transwell permeability assay, and transmission electron microscopy were used to study endothelial TJs in human lung microvascular endothelial cells. TJ protein expression was measured by western blotting or immunohistochemistry.
RESULTS: UFH treatment alleviated lung injury in vivo by reducing IL-6 in bronchoalveolar lavage fluid and protecting TJs in LMVECs. UFH also protected TJs against lipopolysaccharide-stimulated damage and functioned upstream by inhibiting the ERK1/2 MAPK pathway to attenuate endothelial hyperpermeability and downregulating the expression of TJ proteins such as claudin-5, occludin, and ZO-1.
CONCLUSIONS: These findings suggested that UFH has therapeutic potential for sepsis-induced ARDS or ALI through protecting TJs in LMVECs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lung injury; Lung microvascular endothelial cells; Sepsis; Tight junctions; Unfractionated heparin; Vascular permeability

Mesh:

Substances:

Year:  2019        PMID: 30771687     DOI: 10.1016/j.jss.2019.01.020

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  25 in total

Review 1.  Classic Signaling Pathways in Alveolar Injury and Repair Involved in Sepsis-Induced ALI/ARDS: New Research Progress and Prospect.

Authors:  Wenli Li; Duo Li; Yuansen Chen; Halidan Abudou; Haiwang Wang; Jinxia Cai; Yiping Wang; Ziquan Liu; Yanqing Liu; Haojun Fan
Journal:  Dis Markers       Date:  2022-06-18       Impact factor: 3.464

Review 2.  Anticoagulants for people hospitalised with COVID-19.

Authors:  Ronald Lg Flumignan; Vinicius T Civile; Jéssica Dantas de Sá Tinôco; Patricia If Pascoal; Libnah L Areias; Charbel F Matar; Britta Tendal; Virginia Fm Trevisani; Álvaro N Atallah; Luis Cu Nakano
Journal:  Cochrane Database Syst Rev       Date:  2022-03-04

3.  COVID-19 infection-associated coagulopathy: Pathophysiology and clinical implications.

Authors:  Abdulrahman Abutaleb; Sandeep Nathan
Journal:  Interv Neuroradiol       Date:  2021-10       Impact factor: 1.764

Review 4.  Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.

Authors:  Juan A Siordia; Michael Bernaba; Kenji Yoshino; Abid Ulhaque; Sooraj Kumar; Mario Bernaba; Edward Bergin
Journal:  SN Compr Clin Med       Date:  2020-07-15

5.  Up-regulation of TUG1 can regulate miR-494/PDK4 axis to inhibit LPS-induced acute lung injury caused by sepsis.

Authors:  Lin Yang; Li Zhao; Hui Zhang; Peili Chen
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

6.  Prophylactic anticoagulants for people hospitalised with COVID-19.

Authors:  Ronald Lg Flumignan; Jéssica Dantas de Sá Tinôco; Patricia If Pascoal; Libnah L Areias; Marcelly S Cossi; Maria Icd Fernandes; Isabelle Kf Costa; Larissa Souza; Charbel F Matar; Britta Tendal; Virginia Fm Trevisani; Álvaro N Atallah; Luis Cu Nakano
Journal:  Cochrane Database Syst Rev       Date:  2020-10-02

Review 7.  COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure.

Authors:  Monia Marchetti
Journal:  Ann Hematol       Date:  2020-06-24       Impact factor: 3.673

8.  Viscoelastic testing reveals normalization of the coagulation profile 12 weeks after severe COVID-19.

Authors:  Abakar Magomedov; Daniel Zickler; Stoyan Karaivanov; Annika Kurreck; Frédéric H Münch; Julian Kamhieh-Milz; Caroline Ferse; Andreas Kahl; Sophie K Piper; Kai-Uwe Eckardt; Thomas Dörner; Jan Matthias Kruse
Journal:  Sci Rep       Date:  2021-06-25       Impact factor: 4.379

Review 9.  COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation.

Authors:  Wolfgang Miesbach; Michael Makris
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

Review 10.  Coagulopathy of Coronavirus Disease 2019.

Authors:  Toshiaki Iba; Jerrold H Levy; Marcel Levi; Jean Marie Connors; Jecko Thachil
Journal:  Crit Care Med       Date:  2020-09       Impact factor: 9.296

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.